Allergan PLC (NYSE:AGN) dropped 2.8% during trading on Tuesday . The stock traded as low as $237.85 and last traded at $238.36, with a volume of 3,276,598 shares traded. The stock had previously closed at $245.29.

AGN has been the subject of several research analyst reports. Cowen and Company restated a “buy” rating on shares of Allergan PLC in a research note on Tuesday, May 24th. Bank of America Corp. restated a “buy” rating and set a $294.00 price target (up from $287.00) on shares of Allergan PLC in a research note on Wednesday, June 29th. Leerink Swann restated a “buy” rating on shares of Allergan PLC in a research note on Thursday, June 30th. Wells Fargo & Co. restated a “buy” rating on shares of Allergan PLC in a research note on Friday, June 10th. Finally, Vetr lowered Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $275.94 price target for the company. in a research note on Thursday, June 2nd. Six analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Allergan PLC has an average rating of “Buy” and an average target price of $308.54.

The stock has a market cap of $94.50 billion, a P/E ratio of 22.72 and a beta of 0.73. The company has a 50-day moving average price of $246.00 and a 200-day moving average price of $243.40.

Allergan PLC (NYSE:AGN) last released its quarterly earnings data on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.34 by $0.01. The firm earned $3.68 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter last year, the firm earned $4.41 earnings per share. On average, analysts expect that Allergan PLC will post $14.01 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the stock. Evercore Wealth Management LLC raised its position in Allergan PLC by 26.2% in the second quarter. Evercore Wealth Management LLC now owns 153,392 shares of the company’s stock valued at $35,448,000 after buying an additional 31,821 shares during the period. Carnick & Kubik Group LLC bought a new position in Allergan PLC during the second quarter valued at $989,000. Williams Jones & Associates LLC raised its position in Allergan PLC by 1.1% in the second quarter. Williams Jones & Associates LLC now owns 110,544 shares of the company’s stock valued at $25,546,000 after buying an additional 1,242 shares during the period. Kentucky Retirement Systems Insurance Trust Fund bought a new position in Allergan PLC during the second quarter valued at $3,691,000. Finally, Kentucky Retirement Systems bought a new position in Allergan PLC during the second quarter valued at $7,773,000. Institutional investors own 85.25% of the company’s stock.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.